Stem cells hold great promise for both cell-based research and advances in the understanding of diseases, with the subsequent development of new drugs and therapies. Frost & Sullivan feels that newer developments involving MSCs with the aim to provide novel solutions for stem cell research and therapeutics are crucially needed.
Vitro Biopharma is a biotechnology company focused on the development and commercialization of adult stem cell technology for applications in stem cell research, drug development, and cell-based therapeutics to treat a variety of diseases and conditions. The company presently offers a series of tools and technologies to promote the development of stem cell research and clinical applications focusing on mesenchymal stem cells. Vitro Biopharma’s current operational strategy is aimed at increasing the market penetration of its proprietary MSC-based research products, while extending its stem cell segment to include differentiated cells derived from MSCs, such as chondrocytes, endothelial cells, and osteoblasts, ideally prescribed for high throughput screening in drug discovery and development.
Frost & Sullivan is proud to recognize Vitro Biopharma with the 2014 Technology Innovation Leadership Award due to its outstanding performance and excellent business strategy. Vitro Biopharma is one of four companies awarded for advances in Healthcare and Medicine this year. Award criterion include: commitment to innovation, commitment to creativity, stage gate efficiency, commercialization success, application diversity, unmet needs, use of mega trends, pioneering best practices, blue ocean strategy, and aspirational ideals. Click on the image for further details.